{"date":"2025-05-24","count":3,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6472-2025-05-24-1904-3wyyj0","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2025-05-24","time":"19:04:49","subject":"本公司修訂「國內第三次無擔保轉換公司債發行及轉換辦法」之債權人公告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2025-05-24 19:04，「本公司修訂「國內第三次無擔保轉換公司債發行及轉換辦法」之債權人公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6446-2025-05-24-0816-199gnld","company_id":"6446","company":"藥華藥","market":"上市","industry":"生技醫療","date":"2025-05-24","time":"08:16:26","subject":"公告本公司長效型顆粒性白血球生成素P2203之第一期臨床試驗初步結果（Topline Results）","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：藥華藥（6446），2025-05-24 08:16，「公告本公司長效型顆粒性白血球生成素P2203之第一期臨床試驗初步結果（Topline Results）」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6446-2025-05-24-0810-vqkii","company_id":"6446","company":"藥華藥","market":"上市","industry":"生技醫療","date":"2025-05-24","time":"08:10:45","subject":"公告本公司註銷限制員工權利新股減資變更登記完成","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：藥華藥（6446），2025-05-24 08:10，「公告本公司註銷限制員工權利新股減資變更登記完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}